Emd Serono, Inc. company information, Employees & Contact Information

EMD Serono Announces Unprecedented Agreement with U.S. Government to Expand Access to IVF Therapies Yahoo Finance

EMD Serono to Present New Data Highlighting Durable Effects of MAVENCLAD Business Wire

The IT Impact BOSS Publishing

EMD Serono Appoints Miguel Fernández Alcalde to Lead North American Healthcare Business citybiz

EMD Serono Showcases Innovation in Advanced Cancers and Rare Tumors at ASCO 2025 Yahoo Finance

EMD Serono Presents Positive Phase 2 Data for Enpatoran Demonstrating Reduction in Disease Activity in Patients with Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) with Active Lupus Rash Business Wire

EMD Serono Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025 Yahoo Finance

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib Wiley

EMD Serono Launches New Fertility LifeLines™ Portal to Increase Support and Access for Patients Impacted by Infertility PR Newswire

Health Plans Are Confused about Specialty Drug Management Drug Channels

EMD Serono Launches New Sustainable Slim Pack for Fertility Medication PR Newswire

Diversity, Equity, and Inclusion: Translating Clinical Pharmacology for All Wiley

EMD Serono Launches MS-LINK™, a Community to Advance MS Science and Improve Patient Lives PR Newswire

Phase I crossover study of DNA-protein kinase inhibitor peposertib in healthy volunteers: Effect of food and pharmacokinetics of an oral suspension Wiley

EMD Serono Announces Plans for New U.S. Healthcare Headquarters in Boston’s Seaport District Business Wire

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT Yahoo Finance

Rehan Verjee to Lead EMD Serono as Company Advances its Innovative Medicines Strategy in North America PR Newswire

14th Annual EMD Serono Specialty Digest™ Educates Health Plans on Latest Trends in Unmet Payer Needs and Patient-Centric Services PR Newswire

EMD Serono Appoints Zhen Su, M.D., MBA to Chief Medical Officer, North America PR Newswire

MassBio’s® Partnering Week Connects Massachusetts’ Innovation Ecosystem with World-Leading Biopharmas Massachusetts Biotechnology Council

Realizing the promise of Project Optimus: Challenges and emerging opportunities for dose optimization in oncology drug development Wiley

EMD Serono Unveils New MAVENCLAD® Four-Year Data Highlighting Benefits of Early Treatment and Sustained Efficacy Across Multiple Measures of Disease Activity Business Wire

Gary Zieziula Appointed President and Managing Director of EMD Serono PR Newswire

John Walsh, M.D. Joins EMD Serono as Vice President of Neurology & Immunology, US Medical Affairs PR Newswire

Machine Learning in Modeling Disease Trajectory and Treatment Outcomes: An Emerging Enabler for Model-Informed Precision Medicine Wiley

Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases ACS Publications

Richard R. Smith Joins EMD Serono as Senior Vice President and Head of US Fertility and Endocrinology PR Newswire

Expanding Chemical Probe Space: Quality Criteria for Covalent and Degrader Probes | Journal of Medicinal Chemistry ACS Publications

Q&A: MassBio Partnering Week’s innovation champions on how collaboration can accelerate the delivery of new medicines to patients Massachusetts Biotechnology Council

EMD Serono Receives FDA Approval for New GONAL-f® RFF Redi-ject® Pen PR Newswire

EMD Serono Advances Oncology Portfolio and Pipeline with New and Long-term Data in Multiple Cancers at ESMO 2020 PR Newswire

Breakthrough Innovation in Cancer Care From EMD Serono Pipeline to Be Presented at ASCO 2020 PR Newswire

EMD Serono Takes on Exclusive Promotion of Rebif® (interferon beta-1a) in the US PR Newswire

China’s Center for Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany’s Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor Business Wire

Alternatives to rifampicin: A review and perspectives on the choice of strong CYP3A inducers for clinical drug–drug interaction studies Wiley

A Case to Support the Continued Use of Rifampin in Clinical Drug–Drug Interaction Studies Wiley

Merck KGaA, Darmstadt, Germany’s Innovative Oncology Pipeline of DNA Damage Response Inhibitors and Antibody-Drug Conjugates Poised to Advance Cancer Treatment Business Wire

EMD Serono Continues Leadership Role in Product Integrity by Launching Product Tracking Program and Check My Meds™ Smartphone App PR Newswire

FDA Grants Approval for BAVENCIO® (avelumab) MultiVu

MAVENCLAD® (Cladribine) Tablets Now Covered by Express Scripts PR Newswire

TEPMETKO® (Tepotinib) Approved in Japan for Advanced NSCLC with METex14 Skipping Alterations PR Newswire

Study launches of eftilagimod alpha plus avelumab in urothelial cancer Urology Times

Embracing Carers™ expands support for caregivers worldwide PR Newswire

FDA Approves New Version of Gonal-f Prefilled Pen Medical Professionals Reference

EMD Serono Supports Military Community By Providing Access to Fertility Care Through Focused Patient Assistance Programs MultiVu

FDA Approves MAVENCLAD® (Cladribine) Tablets for Multiple Sclerosis MultiVu

Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β Science | AAAS

EMD Serono Appoints Manuel Zafra as New Managing Director for Canada PR Newswire Canada

EMD Serono and Pfizer Announce FDA Approval of Rebif® Rebidose® (interferon beta-1a) PR Newswire

Merck to Present Latest Research from Oncology Portfolio at ESMO 2023 The AI Journal

Embracing Carers™ expands support for caregivers worldwide MultiVu

Specialty Drugs and Health Care Costs The Pew Charitable Trusts

Merck Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor Business Wire

World MS Day 2018: Call for Greater Curiosity to Drive Understanding of the Disease and Future Innovation MultiVu

VIEW on Sales: Gaining Power Through Evidence-based Selling PharmaVoice

Global Survey and Documentary Film Expose Emotional Impact of Multiple Sclerosis MultiVu

FDA Grants Approval for BAVENCIO® (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma 美通社

MAVENCLAD® (cladribine tablets) is available through public drug plans for the majority of eligible Canadians with Relapsing-Remitting Multiple Sclerosis PR Newswire Canada

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT ANSA